Clinical Trials
48 trialsLUCENT-GC-03
Qilu Hospital of Shandong University
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
Guangdong Provincial People's Hospital
Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
Anhui Provincial Cancer Hospital
FRUTIGA
Hutchmed
Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer
Changhai Hospital
Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer
Seoul National University Hospital
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
Fujian Medical University
A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer
Shanghai Zhongshan Hospital
The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer
Huazhong University of Science and Technology
Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer
First Affiliated Hospital of Wenzhou Medical University
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Seoul National University Hospital
Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer
Xijing Hospital
FRACTION-GC
Bristol-Myers Squibb
A Randomized Controlled Trial of Integrated Early Palliative Care for Advanced Gastric Cancer Patients
Yonsei University
Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
Shandong Golden Brick Biotechnology Co., Ltd.
Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer
China Medical University, China
Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS
Asan Medical Center
Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin
Asan Medical Center
RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX
Asan Medical Center
Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
Asan Medical Center
Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy
Samsung Medical Center
Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
Chinese PLA General Hospital
A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
HRYZ Biotech Co.
Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer
Henan Cancer Hospital
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer
AnewPharma
PaFLO
Charite University, Berlin, Germany
Bioinformation Therapy for Gastric Cancer
Fuda Cancer Hospital, Guangzhou
Comparison of Ability of pCLE and WLE for Diagnosis and Cancer Tissue Acquisition in Advanced Gastric Cancer After Chemotherapy Status
Yonsei University
Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer Patients
Peking University
Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer
Guangdong Provincial People's Hospital
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
Fujian Cancer Hospital
Laparoscopic Gastrectomy for Advanced Gastric Cancer
Seoul National University Bundang Hospital
PF299804-AGC
Seoul National University Hospital
TI-2ndAGC
Seoul National University Hospital
Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
Peking University
Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Peking University
Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer
Peking University
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
Fudan University
Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis
Shanghai Zhongshan Hospital
GZH-001
The Second People's Hospital of Sichuan
A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer
Seoul National University Hospital
Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
Samsung Medical Center
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
Samsung Medical Center
IPchemo-AGC
Fudan University
Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)
Samsung Medical Center